|
|||||
|
|
| 受体相互作用蛋白1及其抑制剂研究进展 | |
| 引用本文： | 王占梅, 余静, 郝杰, 王明慧, 廖红, 王进欣. 受体相互作用蛋白1及其抑制剂研究进展[J]. 药学进展, 2018, 42(12): 945-951. |
| 作者姓名： | 王占梅 余静 郝杰 王明慧 廖红 王进欣 |
| 作者单位： | 1.中国药科大学江苏省药物分子设计与成药性优化重点实验室, 江苏 南京210009;2.中国药科大学药物科学研究院新药筛选中心, 江苏 南京 210009 |
| 基金项目： | 江苏省重点研发计划(No.BE2015683) |
| 摘 要： |  受体相互作用蛋白1为细胞程序性坏死通路中极为重要的调节因子, 参与缺血性心脑血管疾病、炎症、神经退行性疾病和肿瘤的发生与发展。因此, 受体相互作用蛋白1作为一个新型的药物靶标引起了广泛关注。综述受体相互作用蛋白1的结构、生物学作用以及近年来受体相互作用蛋白1激酶抑制剂的研究进展。  |
| 关 键 词： | 受体相互作用蛋白1 抑制剂 程序性坏死 疾病 |
Receptor-interacting protein (RIP) kinase family |
|
| WANG Zhanmei, YU Jing, HAO Jie, WANG Minghui, LIAO Hong, WANG Jinxin. Research Progress of Receptor-interacting Protein 1 and Its Inhibitors[J]. Progress in Pharmaceutical Sciences, 2018, 42(12): 945-951. | |
| Authors: | WANG Zhanmei YU Jing HAO Jie WANG Minghui LIAO Hong WANG Jinxin |
| Affiliation: | 1.Key Laboratory of Drug Design and Optimization of Jiangsu Province, China Pharmaceutical University, Nangjing 210009, China;2.New Drug Screening Center, Academy of Pharmaceutical Sciences, China Pharmaceutical University, Nangjing 210009, China |
| Abstract: | Receptor-interacting protein 1 (RIP1) is an extremely important regulatory protein in cell necroptosis, and is involved in the occurrence and development of ischemic cardiovascular and cerebrovascular diseases, inflammation, neurodegenerative diseases and malignant tumors. Therefore, RIP1 has attracted great attention from drug researchers as a new type of drug target. This paper reviewed the structure and biological effects of RIP1 as well as the advances in research on RIP1 kinase inhibitors in recent years. |
| Keywords: | receptor-interacting protein 1 inhibitor programmed necrosis disease |
| 点击此处可从《药学进展》浏览原始摘要信息 | |
| 点击此处可从《药学进展》下载全文 | |